Company: SWKH
Filing Date: 2025-04-29
Form Type: ANNLRPT
Source: 0001628280-25-020720
Chunk: 86

Company: SWK Holdings Corp
Filing Date: 2025-04-29
Form: ANNLRPT
Chunk 86
---
 |
| Inventory                              |     | $                 |   354 |
| Property & equipment, net              |     |                   | 4,635 |
| Intangible assets, net                 |     |                   |   209 |
| Other non-current assets               |     |                   | 1,200 |
| Total assets held for sale, net        |     | $                 | 6,398 |
| Liabilities:                           |     |                   |       |
| Accounts payable & accrued liabilities |     | $                 |   268 |
| Other non-current liabilities          |     |                   |   987 |
| Total liabilities held for sale        |     | $                 | 1,255 |

During the year ended December 31, 2024, there was not a strategic shift for the Company, and accordingly, the Pharmaceutical Development segment does not meet the criteria to be classified as a discontinued operation. As a result, we will continue to report our operational results for the Pharmaceutical Development segment until the sale. The following table shows the net loss before taxes for Enteris (in thousands):

|                       |     | December 31, |   2024 |     |   |   2023 |
|:----------------------|:----|:-------------|-------:|:----|:--|-------:|
| Net loss before taxes |     | $            | -3,718 |     | $ | -9,763 |

<div align='center'>53</div>

#### Note 8. Debt
Revolving Credit Facility

On June 28, 2023, the Company entered into a new Credit Agreement (the “Credit Agreement”) by and among SWK Funding LLC, the Company’s wholly-owned subsidiary (together with the Company, the “Borrower”), the lenders party thereto (“Lenders”), and First Horizon Bank as a Lender and Agent (the “Agent”). The Credit Agreement provides for a revolving credit facility with an initial maximum principal amount of $45.0 million. The Credit Agreement provides that the Company may request one or more incremental increases in an aggregate amount not to exceed $80.0 million, subject to the consent of the Agent and each Lender, at any time prior to the termination of the revolving credit period on June 28, 2026 (the “Commitment Termination Date”). The revolving credit period will be followed by a one-year amortization period, with the final maturity date of the Credit Agreement occurring on June 28,